Immix Biopharma, INC 10-Q quarterly reports

Immix Biopharma's Q2 2026 10-Q filing details substantial capital raises, positive interim clinical trial data for NXC-201, and ongoing operational losses.

Immix Biopharma reports Q1 2026 financial results, highlighting clinical progress for NXC-201 and a strong cash position of $90.6 million.

Immix Biopharma reported increased Q3 losses and a going concern warning, while securing new capital and advancing its NXC-201 CAR-T therapy with positive clinical data and RMAT designation.

Immix Biopharma reported increased net losses in Q2 2025 due to higher R&D expenses for its promising NXC-201 CAR-T therapy, which continues to show strong clinical efficacy and has received key regulatory designations.

Immix Biopharma files an amendment to its original Q1 2025 report to include certifications from the CEO and CFO as required by Sarbanes-Oxley Act.

Immix Biopharma reports a net loss of $4.54 million for Q1 2025, with ongoing clinical trials and CIRM grant reimbursements impacting financial results.

Immix Biopharma's Q3 2024 report reveals increased research and development expenses alongside a net loss, while highlighting progress in clinical trials and a recent $8 million grant award.

Immix Biopharma's Q2 2024 report details increased operating expenses, a net loss, and progress in clinical trials, alongside a recent $8 million grant award.

Immix Biopharma's Q1 2024 report shows increased operating expenses due to ongoing clinical trials and a net loss, but also highlights significant cash inflows from equity offerings.